Almonertinib plus Palbociclib for KRAS-mutated solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs, Almonertinib and Palbociclib, for people with advanced solid tumors that have a KRAS mutation. It aims to see if this new combination can shrink tumors or slow their growth, and it may be an option if your cancer has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a KRAS mutation in your tumor or blood (like G12C, G12D, etc.) and your cancer has not responded to other treatments or there is no standard treatment.
- You have not had chemotherapy or targeted therapy before for your cancer (except neoadjuvant or adjuvant therapy that ended more than 6 months ago).
- You are able to do daily activities with little or no help (ECOG 0 or 1).
- Your organs (heart, blood, liver, kidneys) are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new experimental drug (called TQB2928) combined with a standard targeted therapy pill for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can help when standard EGFR inhibitors are no longer effective.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This study tests a new combination of two drugs, almonertinib and SHR-1701, for people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if this combination can help control the cancer and is safe to use.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
Hear when a new EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.